Market Research Report
Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends
|Published by||BIOINFORMANT WORLDWIDE, LLC||Product code||691737|
|Published||Content info||195 Pages
Delivery time: 1-2 business days
|Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends|
|Published: December 10, 2019||Content info: 195 Pages||
CAR-T cell therapy is a remarkably promising treatment for cancer patients. This emerging treatment is one of the biggest breakthroughs since the introduction of chemotherapy. CAR-T is a type of immunotherapy where doctors collect immune cells from a patient, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells and infuse them back into the patient. The infused cells get multiplied and stay in the body as "living drugs."
In the past, significant successes were made possible by chemotherapy and radiation by killing cancer cells. However, the effects were not permanent. Now, CAR-T cells are providing a compelling alternative. T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of the immune system and they play a key role in directing the immune response and killing cells infected by pathogens.
The purpose of this report is to describe the current status of chimeric antigen receptor T-cells (CAR-T cells), the related patent landscape, funding, deals, research, applications, technologies, the details of the two marketed CAR-T cell products, and the ongoing and late stage clinical trials.
The widespread research activities, worldwide clinical trials and approved treatments (Kymriah and Yescarta) have created a robust CAR-T cell therapy market. This billion dollar market size and its strong growth would not be possible without the remarkable efficacy of Kymriah and Yescarta in treating several types of blood cancers. CAR-T cell therapy has swept the biotech industry by storm, attracting new market participants at a rapid pace.